GSK3 and Cancer

Many of the components of the Wnt signaling pathway are over-expressed or mutated in different tumors [38]. For example, virtually all colon tumors arise from an initiating mutation in the APC gene (85%) or in the P-catenin gene (10-15%) that makes P-catenin resistant to degradation. Axin mutations occur in hepatocellular carcinomas and FRAT1 in T-cell lymphomas. Alterations in these components would be predicted to lead to inappropriate accumulation of P-catenin.

These observations have implications for the development of GSK3 inhibitors to treat diabetes and other diseases, as compounds that target the ATP-binding site, such as SB 216763 and SB 415286, inhibit the phosphorylation of all GSK3 substrates, including Axin and P-catenin. They therefore mimic the Wnt signaling pathway and stimulate the accumulation of P-catenin [32]. The development of GSK3 inhibitors that do not have the potential to be oncogenic may therefore require the identification of compounds that prevent the phosphorylation of glycogen synthase but which do not inhibit the phosphorylation of Axin and P-catenin. This may be possible because Axin and P-catenin appear to bind to GSK3 at sites distinct from glycogen synthase and eIF2B. Mutations in GSK3 have been identified that prevent the phosphorylation of glycogen synthase and eIF2B but not the phosphorylation of Axin and P-catenin, and vice versa [14, 39].

Acknowledgments

Our research on GSK3 is supported by the U.K. Medical Research Council, The Royal Society, Diabetes U.K., AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novo Nordisk and Pfizer.

References

1. Embi, N., Rylatt, D. B., and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107, 519-527.

2. Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9, 2431-2438.

3. Frame, S. and Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16.

4. Cohen, P. and Frame, S. (2001). The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2, 769-776.

5. Ali, A., Hoeflich, K. P., and Woodgett, J. R. (2001). Glycogen synthase kinase-3, properties, functions, and regulation. Chem. Rev. 101, 2527-2540.

6. Picton, C., Woodgett, J. R., Hemmings, B., and Cohen, P. (1982). Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Phosphorylation of site 5 by glycogen synthase kinase-5 (casein kinase-II) is a prerequisite for phosphorylation of sites 3 by glycogen synthase kinase-3. FEBS Lett. 150, 191-196.

7. Fiol, C. J. et al. (1987). Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262, 14042-14048.

8. Welsh, G. I. and Proud, C. G. (1993). Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukary-otic initiation factor eIF-2B. Biochem J. 294, 625-629.

9. Welsh, G. I. et al. (1998). Regulation of eukaryotic initiation factor eIF2B, glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett. 421, 125-130.

10. Woods, Y. L. et al. (2001). The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bs at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355, 609-615.

11. Hughes, K. et al. (1992). Identification of multifunctional ATP-citrate lyase kinase as the a-isoform of glycogen synthase kinase-3. Biochem. J. 288, 309-314.

12. Benjamin, W. B. et al. (1994). ATP citrate-lyase and glycogen synthase kinase-3P in 3T3-L1 cells during differentiation into adipocytes. Biochem. J. 300, 477-482.

13. Fiol, C. J. et al. (1994). A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J. Biol. Chem. 269, 32187-32193.

14. Frame, S., Cohen, P., and Biondi, R. M. (2001). A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell. 7, 1321-1327.

15. ter Haar, E. et al. (2001). Structure of GSK3P reveals a primed phos-phorylation mechanism. Nat. Struct. Biol. 8, 593-596.

16. Dajani, R. et al. (2001). Crystal structure of glycogen synthase kinase 3P: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 105, 721-732.

17. Hughes, K. et al. (1993). Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12, 803-808.

18. Shaw, M., Cohen, P., and Alessi, D. R. (1997). Further evidence that the inhibition of glycogen synthase kinase-3ß by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 416, 307-311.

19. Kim, L., Liu, J., and Kimmel, A. R. (1999). The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 99, 399-408.

20. Bhat, R. V. et al. (2000). Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3ß in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA 97, 11074-11079.

21. Hartigan, J. A. and Johnson, G. V. (1999). Transient increases in intracellular calcium result in prolonged site-selective increases in tau phosphorylation through a glycogen synthase kinase 3ß-dependent pathway. J. Biol. Chem. 274, 21395-21401.

22. Cross, D. A. et al. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.

23. Stambolic, V. and Woodgett, J. R. (1994). Mitogen inactivation of glycogen synthase kinase-3ß in intact cells via serine 9 phosphoryla-tion. Biochem. J. 303, 701-704.

24. Shaw, M. and Cohen, P. (1999). Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett. 461, 120-124.

25. Armstrong, J. L. et al. (2001). Regulation of glycogen synthesis by amino acids in cultured human muscle cells. J. Biol. Chem. 276, 952-956.

26. Williams, M. R. et al. (2000). The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr. Biol. 10, 439-448.

27. Parker, P. J., Caudwell, F. B., and Cohen, P. (1983). Glycogen synthase from rabbit skeletal muscle: effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur. J. Biochem. 130, 227-234.

28. Eldar-Finkelman, H. et al. (1999). Increased glycogen synthase kinase-3 activity in diabetes- and obesity- prone C57BL/6J mice. Diabetes. 48, 1662-1666.

29. Coghlan, M. P. et al. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7, 793-803.

30. Norman, P. (2001). Emerging fundamental themes in modern medicinal chemistry. Drug News Perspect. 14, 242-247.

31. Lochhead, P. A. et al. (2001). Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carbokykinase gene expression. Diabetes. 50, 937-946.

32. Cross, D. A. et al. (2001). Selective small-molecule inhibitors of glyco-gen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77, 94-102.

33. Dale, T. C. (1998). Signal transduction by the Wnt family of ligands. Biochem. J. 329, 209-223.

34. Li, L. et al. (1999). Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 18, 4233-4240.

35. Thomas, G. M. et al. (1999). A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and ß-catenin. FEBS Lett. 458, 247-251.

36. Farr, G. H. R. et al. (2000). Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specification. J. Cell Biol. 148, 691-702.

37. Hoeflich, K. P. et al. (2000). Requirement for glycogen synthase kinase-3 ß in cell survival and NF-kB activation. Nature 406, 86-90.

38. Polakis, P. (2000). Wnt signaling and cancer. Genes Dev. 14, 1837-1851.

39. Fraser, E. et al. (2002). Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J. Biol. Chem. 277, 2176-2185.

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook


Post a comment